RT Journal Article
SR Electronic
T1 Effects of Low-Dose EPA-E on Glycemic Control, Lipid Profile, Lipoprotein(a), Platelet Aggregation, Viscosity, and Platelet and Vessel Wall Interaction in NIDDM
JF Diabetes Care
JO Diabetes Care
FD American Diabetes Association
SP 683
OP 688
DO 10.2337/diacare.16.5.683
VO 16
IS 5
A1 Westerveld, H Tineke
A1 de Graaf, Jacques C
A1 Van Breugel, Hans HFI
A1 Akkerman, Jan Willem N
A1 Sixma, Jan J
A1 Erkelens, D Willem
A1 Banga, Jan Dirk
YR 1993
UL http://care.diabetesjournals.org/content/16/5/683.abstract
AB OBJECTIVE To assess the effects of low-dose eicosapentaenoic acid-ethyl-ester on diabetes regulation, lipid metabolism, blood rheology, and platelet reactivity. RESEARCH DESIGN AND METHODS In a double-blind, randomized, placebo-controlled study, 24 NIDDM subjects received 1800 mg of EPA-E, 900 mg of EPA-E, or a placebo (1656 mg olive oil) daily for 8 wk. RESULTS The EPA: arachidonic acid plasma ratio increased over an 8-wk period, then declined after a 4-wk wash-out period in the fish-oil groups in a dosedependent way. Platelet-activating factor-induced platelet aggregation decreased from 75 ± 7% at wk 0 to 35 ± 21% at wk 8 in the 900-mg group (P = 0.016) and from 72 ± 11 to 40 ± 30% in the 1800-mg group (P = 0.039), but did not change in the placebo group. No effects on A DP- or collagen-induced aggregation could be attributed to EPA-E. In the 1800-mg group low-density-lipoprotein cholesterol increased significantly, without concomitant rise in apolipoprotein B. Triglycerides, glycemic control, lipoprotein (a), blood and plasma viscosity, erythrocyte deformability, and platelet adhesion to and aggregate formation on extracellular endothelial cell matrix were not significantly influenced. CONCLUSIONS Purified EPA-E in doses of 900 and 1800 mg reduces Plateletactivating factor-induced platelet aggregation without negatively affecting glycemic control. Low-density-lipoprotein cholesterol was elevated in the 1800-mg group.